General information
    ACovPid:ACoVP100337
    Trivial Name:IPB03
    Amino Acids Sequence:INASVVNIQKEIDRLNEVAKNLNESLIDLQELGK(Chol)
    Length:34
    C-Terminal Modification:  
    N-Terminal Modification:None
    Chemical Modification:None
    Peptide Source:

    Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) : 2697049

    Source Description:From the heptad repeat region 2 of spike protein of SARS-CoV-2
    Against Virus:

    Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) : 2697049

    Inhibition Value Type:IC50
    Inhibitory Effect:0.947 ± 0.179
    Inhibitory Unit:µM
    Target Domain Name:HR2 domain of SARS-CoV
    Assay:Single-cycle infection assay
    Assay Description:The infectivity of SARS-CoV-2, SARS-CoV, and vesicular stomatitis virus (VSV) for 293T cells or 293T cells stably expressing human ACE2 (293T/ACE2) was determined by a single-cycle infection assay as described previously (PMID: 31619552). To produce pseudoviruses, 293T cells were cotransfected with a backbone plasmid (pNL4-3.luc.RE) that encodes an Env-defective, luciferase reporter-expressing HIV-1 genome and a plasmid expressing the S protein of SARS-CoV-2 or SARS-CoV or the G protein of VSV. Cell culture supernatants containing the released virions were harvested at 48 h posttransfection, filtrated, and stored at −80°C. To measure the inhibitory activity of peptide inhibitors, pseudoviruses were mixed with an equal volume of a serially 3-fold-diluted peptide and incubated at 37°C for 30 min. The mixture was then added to 293T/ACE2 cells at a density of 10^4 cells/100 µl per plate well. After they were cultured at 37°C for 48 h, the cells were harvested and lysed in reporter lysis buffer, and luciferase activity was measured using luciferase assay reagents and a luminescence counter (Promega, Madison, WI, USA). The 50% inhibitory concentration (IC50) was calculated as the final cell culture concentration of an inhibitor that caused a 50% reduction in relative luminescence units (RLU) compared to the level of the virus control subtracted from that of the cell control.
    Anti-CoV activity in vivo:
    Reference:32376627
    Comment:This assay is a Pseudovirus Infection of SARS-CoV-2.
    3D structure:

    Structure Experiment Verified:
    Similar Peptides:ACoVP100246   ACoVP100242   ACoVP100247   ACoVP100122   ACoVP100121

    Target Domain information
    Target Domain Full Name:Heptad repeat 2 (HR2) domain of Severe acute respiratory syndrome coronavirus (SARS-CoV) spike glycoprotein
    Target Type:glycoprotein
    UniprotID [Sequence]:

    P59594 [1145-1184]

    Target Synonyms:Alternative name(s) for spike glycoprotein: E2 Peplomer protein S glycoprotein
    Target Source:

    Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009

    Target Structure:1WNC, 1WYY, 1ZV7, 1ZV8, 1ZVB, 2AJF, 2BEQ, 2BEZ, 2DD8, 2FXP, 2GHV, 2GHW, 2RUM, 2RUN, 2RUO, 3BGF, 3D0G, 3D0H, 3D0I, 3SCI, 3SCJ, 3SCK, 3SCL, 5WRG, 5X4S, 5X58, 5X5B, 5XJK, 5XLR, 5ZVM, 6ACC, 6ACD, 6ACG, 6ACJ, 6ACK, 6CRV, 6CRW, 6CRX, 6CRZ, 6CS0, 6CS1, 6CS2, 6M3W, 6NB6, 6NB7, 6VW1, 6WAQ, 7JN5